Company: ACTG
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0000934549-25-000054
Chunk: 189

Company: ACACIA RESEARCH CORP
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 189
---
,032)(2,696)General and administrative costs - industrial operations(447)(768)General and administrative costs - energy operations138 1,392 General and administrative costs - manufacturing operations4,151 14,026 Amortization of industrial operations and manufacturing operations intangible assets422 $1,323 Total change in general and administrative expenses$4,718 $14,968 

General and administrative expenses includes primarily salaried employee compensation and related personnel costs, administrative office and facilities costs, legal and accounting professional fees, and intangible amortization expenses. The table above includes our Manufacturing Operations general and administrative expenses for the three and nine months ended September 30, 2025, with no comparable period expense as the transaction closed in the fourth quarter of 2024.

The decreases in other general and administrative costs, which relate to our parent company and our Intellectual Property Operations, were primarily due to a decrease in corporate legal fees. The increase in compensation expense for share-based awards was primarily due to increased performance achievement associated with PSUs granted in 2023 based on a probability assessment as of September 30, 2025. Refer to Note 17 to the consolidated financial statements elsewhere herein for additional information regarding compensation expense. The decrease in general and administrative costs of Industrial Operations is due to Printronix’s continued focus on streamlining operating and administrative costs. In addition, our Energy Operations related general and administrative costs contributed an increase of $1.4 million in the nine months ended September 30, 2025 driven by the acquisition of Revolution in 2024. Refer to additional general and administrative change explanations above.

Other Income/Expense 

Equity Securities Investments

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20252024$ Change% Change20252024$ Change% Change(In thousands, except percentage change values)Change in fair value of equity securities$900 $(4,074)$4,974 (122%)$(1,658)$(35,519)$33,861 (95%)Gain on sale of equity securities— — — n/a3,512 28,861 (25,349)(88%)Total net realized and unrealized gain (loss)$900 $(4,074)$4,974 (122%)$1,854 $(6,658)$8,512 (128%)

Our equity securities investments, including the Life Sciences Portfolio and trading securities portfolio, are recorded at fair value at each